Cannell & Co. Annovis Bio, Inc. Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Cannell & Co. holds 10,000 shares of ANVS stock, worth $23,100. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$23,100
Previous $94,000
98.94%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ANVS
# of Institutions
48Shares Held
1.56MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA466KShares$1.08 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$497,1280.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$232,6370.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$229,9920.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$227,5710.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.9M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...